Almirall S.A. and Nuevolution A/S (a wholly owned subsidiary of Nuevolution AB (publ)) announced today that they have entered into a global strategic collaboration focusing on the development and commercialization of Nuevolution’s novel RORgt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis.
As part of the agreement, the parties will also establish a research collaboration for the identification of additional RORgt inhibitors, with an exclusive option for Almirall to use within the dermatological field and with the optional use outside the field of collaboration for Nuevolution.
Almirall will be responsible for funding of any further research as well as pre-clinical, clinical, regulatory and commercial activities. Nuevolution will be responsible for funding of any of its own research.
Nuevolution will receive an upfront payment of EUR 11.2 million (SEK 109.4 million*), and is eligible to receive development and regulatory milestone payments of up to in total maximum of EUR 172 million (SEK 1.7 billion*) provided successful development, and tiered commercial sales milestones of up to in total maximum of EUR 270 million (SEK 2.6 billion*). Nuevolution would further be entitled to receive tiered royalties on future net sales.
“We are extremely excited about entering into this collaboration with Almirall,” said Alex Haahr Gouliaev, CEO of Nuevolution and continued, “Almirall is a world leading pharmaceutical company in the field of treating dermatological diseases, and through the partnership with Almirall our program has found a strong partner for the continued development and later commercialization. We are looking forward to an excellent working relationship with Almirall.”
Eduardo Sanchiz, CEO of Almirall, commented: “This agreement with Nuevolution will allow us to develop RORgt inhibitors for the potential treatment of Dermatology diseases and Psoriatic Arthritis, and this program includes novel NCEs with potential to be one of the first entries into a new class of oral non-steroidal anti inflammatories. We are very pleased with this strategic collaboration with Nuevolution, which reinforces our pipeline and brings an additional potential growth driver to Almirall, as we continue to position ourselves as a leading Dermatology player. It also shows our lasting commitment to bringing innovation in from the best sources”.
About payment scheme
The upfront payment is paid to Nuevolution upon signing of the collaboration agreement, subject to standard payment terms, and represent a guaranteed payment. Pre-clinical, clinical and regulatory milestone payments are contingent on successful development, and commercial milestones are contingent on successful achievement of sales milestones. Therefore, none of these payments are guaranteed. Payments from Almirall may be subject to Spanish withholding tax, which may be deductible in Nuevolution’s Danish corporate tax. (Exchange rate 1,00 EUR – 9,7667 SEK)
For more information, please visit almirall.com.